Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TRC 4186

Drug Profile

TRC 4186

Alternative Names: TRC-4186; TX-41XX

Latest Information Update: 23 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Torrent Pharmaceuticals
  • Class Heart failure therapies; Hydrazines; Pyridinium compounds; Small molecules; Sulfones; Thiophenes
  • Mechanism of Action Advanced glycosylation end product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic complications; Heart failure

Most Recent Events

  • 23 Feb 2018 TRC 4186 is still in phase II trials for Diabetic complications and Heart failure (Torrent Pharma pipeline, February 2018)
  • 13 Aug 2015 No recent reports on development identified - Phase-II for Diabetic complications/Heart failure associated with hyperglycaemia/diabetes (Adjunctive treatment) in India, Netherlands, Russia, Serbia, United Kingdom (PO)
  • 11 Apr 2012 Torrent Pharmaceuticals completes a phase II trial in India, the Netherlands, Russia, Serbia, and the United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top